AI-native biotech research
Your thesis. Compiled.
Most biotech platforms put AI on top of a database. BioSniper built the data, source links, and research workflow for AI—so your criteria can be checked across every covered biotech company, with sources.
See supported fields and evidence rules. How we verify →
This section displays a stored company summary and available source references. It does not show an independently verified complete protocol run.
Rocket Pharmaceuticals Inc. (RCKT) is a fully integrated, commercial-stage biotechnology company focused on developing and commercializing genetic therapies for rare and life-threatening diseases, with a primary emphasis on inherited cardiovascular disorders and one FDA-approved product for an ultra-rare indication.
- Rocket Pharmaceuticals is a fully integrated, late-stage biotechnology company focused on genetic therapies for rare and often fatal diseases [sec · filed 2026-04-06].
- The company's first FDA-approved product, KRESLADI™, was approved in March 2026 under the accelerated approval pathway for the treatment of severe Leukocyte Adhesion Deficiency-I [sec_mda · as of 2026-08-10].
- As of 2026-06-30, the company reported cash & equivalents of $224.5M, shareholders' equity of $368.8M, and net income of $123.2M, with $0.0M in total revenue [sec].
- The company operates a ~100,000 sq. ft. in-house AAV cGMP manufacturing facility in Cranbury, New Jersey to support clinical and future commercial activities [sec · filed 2026-04-06].
- In September 2026, the company announced FDA alignment on continued enrollment and dosing for the pivotal Phase 2 trial of RP-A501 for Danon disease [news · published 2026-09-15].
What works
- First FDA-approved product (KRESLADI™) achieved in March 2026, demonstrating regulatory execution capability [sec · filed 2026-04-06].
- Strong cash position of $224.5M as of 2026-06-30, bolstered by a $180M sale of a Rare Pediatric Disease Priority Review Voucher [sec_mda · as of 2026-08-10].
- In-house AAV cGMP manufacturing facility provides vertical integration and potential for scaled production [sec · filed 2026-04-06].
- Leadership team has a proven track record of over 20 successful U.S. and international drug approvals and launches [sec · filed 2026-04-06].
What to weigh
- No product revenue generated to date; KRESLADI™ is not expected to generate material revenue in the near term due to the ultra-rare patient population [sec_mda · as of 2026-08-10].
- The company implemented a 30% workforce reduction and deprioritized Fanconi Anemia and Pyruvate Kinase Deficiency programs as part of a strategic realignment [sec · filed 2026-04-06].
- Reliance on a single approved product for an ultra-rare indication creates concentration risk; commercial scalability is uncertain [sec_mda · as of 2026-08-10].
- The RP-A501 program for Danon disease was previously under FDA clinical hold, indicating regulatory and clinical development risks [sec · filed 2026-04-06].
From the filings
Quoted directly from source documents.
FDA approval of KRESLADI™
“On March 27, 2026, Rocket announced FDA approval of KRESLADI™.”
SEC filings · April 6, 2026
Workforce reduction of approximately 30%
“the Company implemented a reduction in the workforce of approximately 30%”
SEC filings · April 6, 2026
Catalyst timeline
- 2020-07-06 · Phase 1 Start: Gene Therapy for Pyruvate Kinase Deficiency (PKD) — Initiation of a Phase I clinical trial evaluating safety of autologous CD34+ cells transduced with a lentiviral vector carrying the coRPK gene.
- 2023-08-29 · Phase 1 Start: RP-A601 (PKP2-ACM) — Start of a Phase 1 dose escalation trial for an AAVrh.74 vector containing the human PKP2a coding sequence in subjects with arrhythmogenic cardiomyopathy.
- 2023-09-05 · Phase 2 Start: RP-A501 (Danon Disease) — Initiation of a Phase 2 study evaluating gene therapy for Danon disease.
Risks & what to watch (4)›
Key risks
- No product revenue — KRESLADI™ is not expected to generate material revenue in the near term [sec_mda · as of 2026-08-10].
- Workforce reduction — 30% workforce reduction and deprioritization of two programs indicate operational strain [sec · filed 2026-04-06].
- Clinical hold history — RP-A501 was under FDA clinical hold, highlighting regulatory risk in pivotal trials [sec · filed 2026-04-06].
- Ultra-rare market — KRESLADI™ addresses an ultra-rare indication, limiting commercial upside [sec_mda · as of 2026-08-10].
What to watch
- Progress of the RP-A501 pivotal Phase 2 trial for Danon disease following FDA alignment in September 2026 [news · published 2026-09-15].
- Commercial launch execution and revenue generation from KRESLADI™ for LAD-I [sec_mda · as of 2026-08-10].
- Advancement of cardiovascular pipeline programs RP-A601 (PKP2-ACM) and RP-A701 (BAG3-DCM) [sec_mda · as of 2026-08-10].
- Cash runway and expense management following the 30% workforce reduction and PRV sale [sec · filed 2026-04-06].
Sources: Catalysts · News · SEC filings · SEC MD&A · Generated October 9, 2026 · How we verify sources →
Built on the records biotech decisions depend on.
927 active company records. Seven public-source families support research; coverage and source dates vary by company.
Company fundamentals
SEC filings, runway, and financing
Clinical development
Programs, trials, endpoints, and readouts
Regulatory + science
FDA, PubMed, and patent records
Market + event context
Active-company scope: 927 records; inspect dated market, news and catalyst coverage.
Biotech Pulse
Live market · upcoming catalysts · curated insights — all at a glance.
XBI
$147.86+2.45%
IBB
$204.06+1.02%
New Trials Initiated
5,652
FDA Approvals
399
Partnership Deals
30,449
Phase 3 Completion
33%
Upcoming FDA Catalysts
PDUFA dates, AdCom meetings, readouts — free, no login.
Catalogue counts are database estimates across all stored records, not counts of complete research-ready companies. The active-company scope above uses a separate count.
Recent M&A
AI-native, from the data up
Not AI added to a database. A research system built for AI.
Tell BioSniper what matters. It checks every covered biotech company and shows the evidence—so you do not have to research them one by one.